RIGHTMINDER
29.3.2017 08:02:54 CEST | Business Wire | Press release
With the exponential growth of the aged care industry, cost and care issues are prevalent not only in the UK and Europe but globally. ConnectUs Life Pty Ltd, a specialist care-related services provider has launched RightMinder®, an app that leverages advancements in wearable technology and the increase in availability and use of affordable smartwatches. Coinciding with the release of Android Wear 2.0, RightMinder® caters to the elderly, those in need, pre-teens and Professional Carers. Available in multiple languages and in over 136 countries, RightMinder® delivers a patent-pending solution providing fall detection, first alert monitoring and alerts, GPS location reporting, and multiple first alert carer connections.
RightMinder® has been created to connect ‘wearers’ and ‘carers’. Ben Slater, ConnectUs Life CIO says, ”Our core focus is to ensure wearers maintain meaningful independence with an efficient, yet discreet safety and security alert system. Anyone can use RightMinder® without lock-in contracts, nor do they need expensive custom hardware.” Mr Slater says, “Our First Alert Carers are not only from the family & friends orientated network, but also paid professional Carers too.”
Whilst RightMinder® is specifically designed for Android smartwatches (for wearers), the First Alert and Fall Detection functionality is also available on the mobile phone itself, so anyone can use RightMinder® without requiring a smartwatch. However, RightMinder® strongly recommends using a smartwatch for safety and as a discreet alternative to “the big red emergency button” or pendant. Mr Slater says, “We are extremely encouraged by the acceptance of smartwatch technology amongst our focus groups. Wearers have embraced smartwatch technology when paired with the RightMinder® app. RightMinder® has proven to be very easy to use and manage, despite the underlying complexity of the algorithms utilised.”
RightMinder® wearers are securely connected to one or more carers who can then monitor battery life, location and access fast-touch call buttons. If a Wearer triggers a Fall Detection, or if they send an emergency First Alert, their carers all receive immediate notifications and emails to raise an emergency response. Carers then have the option to locate or call their wearers immediately. Additionally when battery life gets low, notifications are also sent to both wearer and carers.
RightMinder® also extends to people living with disabilities such as MS, dementia, brain trauma, epilepsy and for other high need individuals.
RightMinder® helps reduce the level of dependence on professional operators and on tax funded government assistance.
Contrary to the notion that technology can be complicated, RightMinder® is easy-to-use with a user-friendly interface that has been designed to benefit users who are wearers and carers. Alerting carers is now fast, simple and discreet for any RightMinder® wearer.
The convenience that comes with using the app, in addition to the affordability of the innovative concept, gives independence and empowerment to wearers and comfort to carers like never before, even if wearers and carers live countries apart.
RightMinder® aims for peace of mind without being front of mind.
RightMinder® is available on Google Play Store for Carers and Wearers and coming soon to the Apple App Store (for Carers).
For a full video of the app, please see https://www.youtube.com/watch?v=c2XF2YPabDc .
View source version on businesswire.com: http://www.businesswire.com/news/home/20170328006424/en/
Contact:
RightMinder
Drew Steptoe, Joint MD and CEO.
+61 423 009 082
drew@connectus.life
or
Ben
Slater, Joint MD and CIO.
+61 433 773 585
ben@connectus.life
www.connectus.life
| www.rightminder.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release
Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom